Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Patient Versus Physician Variation in Use of Transradial Percutaneous Coronary Intervention.

Shamim S, Tang F, Safley D, Jones P, Spertus JA, Baklanov D.

Am J Cardiol. 2017 Mar 30. pii: S0002-9149(17)30343-0. doi: 10.1016/j.amjcard.2017.03.020. [Epub ahead of print]

PMID:
28495430
2.

State of HIV in the US Deep South.

Reif S, Safley D, McAllaster C, Wilson E, Whetten K.

J Community Health. 2017 Feb 28. doi: 10.1007/s10900-017-0325-8. [Epub ahead of print]

PMID:
28247067
3.

Costs Associated With Access Site and Same-Day Discharge Among Medicare Beneficiaries Undergoing Percutaneous Coronary Intervention: An Evaluation of the Current Percutaneous Coronary Intervention Care Pathways in the United States.

Amin AP, Patterson M, House JA, Giersiefen H, Spertus JA, Baklanov DV, Chhatriwalla AK, Safley DM, Cohen DJ, Rao SV, Marso SP.

JACC Cardiovasc Interv. 2017 Feb 27;10(4):342-351. doi: 10.1016/j.jcin.2016.11.049.

PMID:
28231901
4.

Test site predicts HIV care linkage and antiretroviral therapy initiation: a prospective 3.5 year cohort study of HIV-positive testers in northern Tanzania.

Reddy EA, Agala CB, Maro VP, Ostermann J, Pence BW, Itemba DK, Safley D, Yao J, Thielman NM, Whetten K.

BMC Infect Dis. 2016 Sep 20;16:497. doi: 10.1186/s12879-016-1804-8.

5.

Training the next generation of invasive cardiologists: Feasibility of implementing a trans-radial access program at an academic hospital.

Stolker JM, Hadid M, Hussain ZM, Rough SJ, Ibrahim M, Kennedy KF, Safley DM, Baklanov DV, Neumayr RH.

Cardiovasc Revasc Med. 2016 Oct - Nov;17(7):431-437. doi: 10.1016/j.carrev.2016.05.006. Epub 2016 Jun 16.

PMID:
27460342
6.

Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.

Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L; DAPT Study Investigators..

JAMA. 2016 Apr 26;315(16):1735-49. doi: 10.1001/jama.2016.3775. Erratum in: JAMA. 2016 Jul 19;316(3):350. JAMA. 2016 Jul 19;316(3):350.

7.

Association between health status and long-term mortality after percutaneous revascularization of peripheral artery disease.

Bunte MC, House JA, Spertus JA, Cohen DJ, Marso SP, Safley DM.

Catheter Cardiovasc Interv. 2016 May;87(6):1149-55. doi: 10.1002/ccd.26442. Epub 2016 Feb 19.

PMID:
26892836
8.

Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial.

Lincoff AM, Mehran R, Povsic TJ, Zelenkofske SL, Huang Z, Armstrong PW, Steg PG, Bode C, Cohen MG, Buller C, Laanmets P, Valgimigli M, Marandi T, Fridrich V, Cantor WJ, Merkely B, Lopez-Sendon J, Cornel JH, Kasprzak JD, Aschermann M, Guetta V, Morais J, Sinnaeve PR, Huber K, Stables R, Sellers MA, Borgman M, Glenn L, Levinson AI, Lopes RD, Hasselblad V, Becker RC, Alexander JH; REGULATE-PCI Investigators..

Lancet. 2016 Jan 23;387(10016):349-56. doi: 10.1016/S0140-6736(15)00515-2. Epub 2015 Nov 5. Erratum in: Lancet. 2016 Mar 19;387(10024):1162. Boudoulas, Dean [corrected to Boudoulas, Konstantinos D.]. Lancet. 2016 Mar 19;387(10024):1162.

PMID:
26547100
9.

Impact of Glycoprotein IIb/IIIa Inhibition in Contemporary Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the National Cardiovascular Data Registry.

Safley DM, Venkitachalam L, Kennedy KF, Cohen DJ.

JACC Cardiovasc Interv. 2015 Oct;8(12):1574-82. doi: 10.1016/j.jcin.2015.04.031.

10.

Images in Vascular Medicine. Rapidly progressive arterial aneurysms in a patient with Ehlers-Danlos syndrome.

Safley DM, Laster SB, Schmidt L, Davis JR.

Vasc Med. 2016 Feb;21(1):71-2. doi: 10.1177/1358863X15592965. Epub 2015 Jun 30. No abstract available.

PMID:
26129734
11.

Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial.

Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L; Dual Antiplatelet Therapy (DAPT) Study Investigators..

JAMA. 2015 Mar 17;313(11):1113-21. doi: 10.1001/jama.2015.1671. Erratum in: JAMA. 2016 Jul 5;316(1):105. JAMA. 2016 Jul 5;316(1):105. JAMA. 2015 Jun 2;313(21):2185.

12.

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators..

N Engl J Med. 2014 Dec 4;371(23):2155-66. doi: 10.1056/NEJMoa1409312. Epub 2014 Nov 16.

13.

The kidney connection: holy grail or wild goose chase?

Safley DM, Chhatriwalla AK.

JAMA Intern Med. 2014 Nov;174(11):1851-2. doi: 10.1001/jamainternmed.2014.3139. No abstract available.

PMID:
25222338
14.

Quality of life benefits of percutaneous coronary intervention for chronic occlusions.

Safley DM, Grantham JA, Hatch J, Jones PG, Spertus JA.

Catheter Cardiovasc Interv. 2014 Oct 1;84(4):629-34. doi: 10.1002/ccd.25303. Epub 2013 Dec 19.

15.

Costs of transradial percutaneous coronary intervention.

Amin AP, House JA, Safley DM, Chhatriwalla AK, Giersiefen H, Bremer A, Hamon M, Baklanov DV, Aluko A, Wohns D, Mathias DW, Applegate RA, Cohen DJ, Marso SP.

JACC Cardiovasc Interv. 2013 Aug;6(8):827-34. doi: 10.1016/j.jcin.2013.04.014. Epub 2013 Jul 17.

16.

Comparison of costs between transradial and transfemoral percutaneous coronary intervention: a cohort analysis from the Premier research database.

Safley DM, Amin AP, House JA, Baklanov D, Mills R, Giersiefen H, Bremer A, Marso SP.

Am Heart J. 2013 Mar;165(3):303-9.e2. doi: 10.1016/j.ahj.2012.10.004. Epub 2012 Nov 15.

PMID:
23453097
17.

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.

Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteză M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; TRILOGY ACS Investigators..

N Engl J Med. 2012 Oct 4;367(14):1297-309. doi: 10.1056/NEJMoa1205512. Epub 2012 Aug 25.

18.

Percutaneous transluminal angioplasty: association between depressive symptoms and diminished health status benefits.

Smolderen KG, Safley DM, House JA, Spertus JA, Marso SP.

Vasc Med. 2011 Aug;16(4):260-6. doi: 10.1177/1358863X11415568.

PMID:
21828173
19.

Comparison of bleeding complications using arterial closure device versus manual compression by propensity matching in patients undergoing percutaneous coronary intervention.

Allen DS, Marso SP, Lindsey JB, Kennedy KF, Safley DM.

Am J Cardiol. 2011 Jun 1;107(11):1619-23. doi: 10.1016/j.amjcard.2011.01.049. Epub 2011 Mar 21.

PMID:
21420052
20.

Changes in myocardial ischemic burden following percutaneous coronary intervention of chronic total occlusions.

Safley DM, Koshy S, Grantham JA, Bybee KA, House JA, Kennedy KF, Rutherford BD.

Catheter Cardiovasc Interv. 2011 Sep 1;78(3):337-43. doi: 10.1002/ccd.23002. Epub 2011 Mar 16.

PMID:
21413136

Supplemental Content

Loading ...
Support Center